NCT03279146View on ClinicalTrials.gov

A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

June 9, 2018

Study Completion Date

June 16, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Tenofovir exalidex (TXL)

Oral formulations

Trial Locations (1)

Unknown

Quotient Clinical, Nottingham

Sponsors
All Listed Sponsors
lead

ContraVir Pharmaceuticals, Inc.

INDUSTRY